Two patients have been administered the initial dosage of SMART101, an allogeneic cell therapy created from donor mobilized peripheral blood stem cells which have been converted into T-cell progenitors utilizing the ProTcell treatment platform by Smart Immune.

Ionis declared encouraging preliminary findings from Phase 3 trial of Olezarsen in patients suffering from familial chylomicronemia syndrome.

YS Biopharma Co., Ltd., pledged to discovery, develop, produce, and supply innovative vaccines and therapeutic biologics for infectious illnesses and cancer.

Remegen's Novel Medication Telitacicept (RC18) Achieves Favorable Phase III Outcomes, Applied for a Secondary Use in Managing Rheumatoid Arthritis.

Mesentech recently revealed that its Phase 1 trial has begun, and the initial patients have already received their doses of MES1022.

Elpiscience Biopharmaceuticals has revealed that the initial patient has received a dose in a Phase 1 clinical study of the anti-LILRB2 monoclonal antibody ES009 in Australia.

Edgewise Therapeutics, Inc., has initiated the participation induction for GRAND CANYON, an international principal examination of EDG-5506 designed for Becker patients.

Arcturus Therapeutics and the Cystic Fibrosis Foundation continue partnership to further the development of ARCT-032, an experimental mRNA therapy for Cystic Fibrosis.

Inozyme Pharma reports encouraging preliminary results from ongoing INZ-701 phase 1/2 studies in adults with ENPP1 and ABCC6 (PXE) deficiencies.

Omega Therapeutics, Inc. reported positive early findings from the first two doses of its Phase 1/2 MYCHELANGELO™ I study on OTX-2002. The study focuses on hepatocellular carcinoma patients and others with solid tumors linked to the c-MYC gene.

Immunovant, Inc. recently revealed preliminary results of a Phase 1 clinical trial for IMVT-1402.

Nippon Kayaku Co., Ltd. and Celltrion Healthcare Japan K.K. have gained approval to manufacture and sell various Adalimumab BS Subcutaneous Injections and Pens in Japan.